Optos
MARLBOROUGH, MA, November 29, 2007 – Optos, a leading medical technology company for the design, development, manufacturing, and marketing of retinal imaging devices, will introduce its newest device - P200MA - at the American Society of Retinal Specialists’ (ASRS) annual meeting taking place December 1st - 5th, 2007 in Indian Wells, CA. The P200MA device enables retinal specialists to perform the
optomap®
fa Medical Procedure, which is a dynamic, ultra-widefield, fluorescein angiography exam providing for the first time a simultaneous, pole-to-periphery view of the retina.
“Given the widefield view of the fundus provided by this new technology, the optomap® fa delivers enhanced angiographic information that aids in the detection and characterization of retinovascular diseases,” stated Ivan J. Suñer, MD, Associate Professor, Duke University Eye Center. “The optomap® fa provides everything that a conventional angiography system does including high image resolution to help us diagnose the extent of macular degeneration and other posterior pole diseases, while also providing unparalleled dynamic peripheral views of the retina all in the same amount of time for the patient and photographer.”
The P200MA device features three retinal imaging procedures that include: optomap® Retinal Exam, optomap® plus Medical Retinal Exam, and optomap® fa Medical Procedure. The P200MA device provides a new imaging platform for retinal specialists that enables a simultaneous, pole-to-periphery view of the retina to aid in disease detection, treatment determination and post treatment assessment. The device will be particularly helpful in providing clinically useful information for the treatment of diabetic patients. Commercial launch of the new device is scheduled for early 2008.
“We are very excited about the prospects for our new P200MA device in the medical care market,” stated Thomas W. Butts, Chief Executive Officer, Optos plc. “The ultra-widefield image of the retina that this device captures responds directly and uniquely to the demographic and lifestyle trends that are raising certain eye and non-eye diseases, including diabetes, to epidemic levels.”
ASRS attendees are encouraged to visit the Optos booth, #22, to learn more about the new device and receive a complementary optomap® image.
Note to Editors
Optos plc is a leading and rapidly growing medical technology company for the design, development, manufacturing and marketing of devices that image the retina, the light-sensitive area at the back of the eye. Optos' platform technology is the Panoramic200 Scanning Laser Ophthalmoscope device - known as the P200. In a quarter of a second the P200 device produces a high resolution image of up to 200 degrees or approximately 82 percent of the retina in a single capture. The image - branded the optomap® Retinal Exam - provides eye care practitioners with clinically useful information that facilitates the early detection of disorders and diseases evidenced in the retina, such as glaucoma, diabetic retinopathy and age-related macular degeneration.
The Company has gained regulatory clearance (CE and FDA 510(k)) to market a second device - P200MA. The P200MA is aimed at the specialist ophthalmic and medical as opposed to the primary care market. It is designed to produce an angiographic retinal image called optomap® fa Medical Procedure by providing enhanced diagnostic, monitoring and treatment capabilities. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as diabetes, hypertension and certain cancers. Optos’ technology provides an unequalled combination of widefield retinal imaging, speed and convenience for both practitioner and patient and can help save sight and save lives.
Optos plc is headquartered in Dunfermline, Scotland and was admitted to the Main Market of the London Stock Exchange on 15 February 2006 trading under the symbol OPTS.
# # #